NCT00866671 - Observational Study of Nelarabine in Children and Young Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Leukaemia, Lymphoblastic, Acute

Interventions

DRUG

nelarabine

Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.

Trial Locations (31)

2100

GSK Investigational Site, Koebenhavn Oe

20246

GSK Investigational Site, Hamburg

28009

GSK Investigational Site, Madrid

28047

GSK Investigational Site, Madrid

28660

GSK Investigational Site, Boadilla Del Monte (Madrid)

31096

GSK Investigational Site, Haifa

33076

GSK Investigational Site, Bordeaux

40137

GSK Investigational Site, Bologna

44093

GSK Investigational Site, Nantes

45122

GSK Investigational Site, Essen

52621

GSK Investigational Site, Ramat Gan

54511

GSK Investigational Site, Vandœuvre-lès-Nancy

59037

GSK Investigational Site, Lille

75475

GSK Investigational Site, Paris

75571

GSK Investigational Site, Paris

75935

GSK Investigational Site, Paris

84101

GSK Investigational Site, Beersheba

117997

GSK Investigational Site, Moscow

119049

GSK Investigational Site, Moscow

350007

GSK Investigational Site, Krasnodar

Unknown

GSK Investigational Site, Aahur N

GSK Investigational Site, Odense C

GSK Investigational Site, Petah Tikva

GSK Investigational Site, Bydgoszcz

DK-9100

GSK Investigational Site, Aalborg

3015 GJ

GSK Investigational Site, Rotterdam

20-093

GSK Investigational Site, Lublin

00-576

GSK Investigational Site, Warsaw

02-781

GSK Investigational Site, Warsaw

50-345

GSK Investigational Site, Wroclaw

08035

GSK Investigational Site, Barcelona